Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

PREG-LAB

Financiado

Distinctive characterization of regulatory plasma cells and pro inflammatory B c...

Distinctive characterization of regulatory plasma cells and pro inflammatory B cells in immunity their origins molecular properties and cellular fates. B cells can act both as negative regulators and as drivers of immunity through the production of cytokines. Through secretion of interleukin (IL)-10 B cells inhibited immunity in autoimmune and infectious diseases. For instance, I... ver más

31/12/2021

INSERM

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100%

3 Participantes

INSERM

1.92M€ | Lider

SHUTON

DRFZ

79.56K€ | Participante

Proyectos interesantes

PID2021-128244OB-I00 REDES DE MICRORNAS REGULADORAS EN TOLERANCIA DE CELULAS B Y... 345K€ Cerrado

RTI2018-094440-B-I00 REPERTORIO, INMUNOPATOLOGIA Y TERAPIA DIRIGIDA A LOS LINFOCI... 242K€ Cerrado

INSPIRE IN depth SPatiotemporal dissection of autoimmunity induced I... 2M€ Cerrado

SAF2015-69829-R CELULAS B DE LA ZONA MARGINAL; SINDROME DE SJOGREN, AUTOINMU... 230K€ Cerrado

SAF2011-23317 EL PAPEL DE LA AUTOFAGIA CELULAR EN LA TOLERANCIA CENTRAL Y... 169K€ Cerrado

RTI2018-097414-B-I00 MECANISMOS DE TOLERANCIA EN LA DIABETES DE TIPO 1: PROCESAMI... 182K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 72 meses Fecha Inicio: 2015-12-14
Fecha Fin: 2021-12-31

Presupuesto del proyecto 2M€

Descripción del proyecto B cells can act both as negative regulators and as drivers of immunity through the production of cytokines. Through secretion of interleukin (IL)-10 B cells inhibited immunity in autoimmune and infectious diseases. For instance, IL-10 from B cells drove complete recovery from disease in experimental autoimmune encephalomyelitis (EAE), the primary animal model for multiple sclerosis (MS), while a lack of IL-10 production by B cells resulted in a severe chronic EAE. B cells can also suppress immunity via IL-35. Human B cells might similarly play inhibitory roles. In few patients with immune-mediated diseases B cell depletion therapy with Rituximab was associated with exacerbation of symptoms, or onset of new pathologies. Conversely, an opposite role of B cells as drivers of immunity was highlighted by the beneficial effect of Rituximab in some patients with rheumatoid arthritis or MS. Clinical improvement often precedes reduction in autoantibody levels in Rituximab treated patients, indicating that B cell-mediated pathogenesis is largely antibody-independent. A candidate factor for the deleterious effects of B cells in MS is IL-6. IL-6 secretion is a major mechanism of B cell-mediated pathogenesis in EAE, and B cells from MS patients produced more IL-6 than cells from healthy individuals. There is now an urgent need for the characterization of the phenotypes of the B cells producing IL-6, IL-10, and IL-35 in vivo at single cell and molecular levels. Markers for these cells might allow understanding the paradoxical effects of B cell-depletion therapy, and guide the development of novel agents depleting distinctively pro-inflammatory B cells, while sparing the remaining of the B cell compartment. Using advanced genetic models to identify and track cytokine-expressing cells, our project aims at characterizing B cells with pro- and anti-inflammatory functions in mice in vivo, to subsequently guide the identification of comparable markers in human.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores